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Aims During restenosis, vascular smooth muscle cells (VSMCs) migrate from the vascular media to the developing neointima.
Preventing VSMC migration is therefore a therapeutic target for restenosis. Drugs, such as prostacyclin analogues, that
increase the intracellular concentration of cyclic adenosine monophosphate (cAMP) can inhibit VSMC migration, but
the mechanisms via which this occurs are unknown. Two main downstream mediators of cAMP are protein kinase A
(PKA) and exchange protein directly activated by cAMP (Epac). This study has examined the effects of the prostacyclin
analogue beraprost on VSMC migration and investigated the intracellular pathways involved.
Methods
and results
In a chemotaxis chamber, human saphenous vein VSMCmigrated towards a platelet-derived growth-factor-BB (PDGF)
chemogradient. Incubation with therapeutically relevant concentrations of cAMP-producing agonist beraprost signifi-
cantly decreased PDGF-induced migration. Direct activation of either PKA or Epac inhibited migration whereas inhib-
ition of PKA did not prevent the anti-migratory effect of beraprost. Direct activation of Epac also prevented hyperplasia
in ex vivo serum-treated human veins. Using fluorescence resonance energy transfer, we demonstrated that beraprost
activated Epac but not PKA. The mechanisms of this Epac-mediated effect involved activation of Rap1 with subsequent
inhibition of RhoA. Cytoskeletal rearrangement at the leading edge of the cell was consequently inhibited. Interestingly,
Epac1 was localized to the leading edge of migrating VSMC.
Conclusions These results indicate that therapeutically relevant concentrations of beraprost can inhibit VSMC migration via a
previously unknown mechanism involving the cAMP mediator Epac. This may provide a novel target that could blunt
neointimal formation.
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1. Introduction
The most common clinical interventions in coronary artery disease are
balloon angioplasty followed by stent emplacement or coronary artery
bypass graft. Both these treatments are associated with neointimal
hyperplasia resulting in restenosis and vessel reocclusion.1,2 While ad-
vancements have been made in stent design, alternative drug strategies
are required to significantly benefit patient outcomes.3 One of the
essential cellular processes involved in neointimal hyperplasia is an
increase in migration of VSMC from the media to the intima.4 This cel-
lular process has yet to be successfully targeted in restenosis. At a
cellular level, VSMC migration is initiated by growth factors such as
platelet-derived growth-factor-BB (PDGF), cytokines (for example tu-
mour necrosis factor-a), and extracellular matrix components.4 These
mediators stimulate migration in a spatially and temporally organized
process. Initially, a remodelling of the actin cytoskeleton occurs
throughout the cell resulting in protrusion of a leading edge.5 This lead-
ing edge extends towards a chemotactic stimulus (for example along a
PDGF concentration gradient), assisted by the actions of matrix metal-
loproteinases which degrade the extracellular matrix.6 Movement of
the cell occurs via the actomyosin motors which generate force.5
The complex guidance cues and intracellular pathways which regulate
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this migration process in VSMC are still unclear. It is known that
monomeric G-proteins have an integral and interdependent role in
migration.4,7 In particular, the role of RhoA has been characterized in
many cell types including VSMC.7–9 RhoA regulates actin polymeriza-
tion via actin-binding proteins involved in focal contact formation with
integrins as well as regulating the activity of myosin II.10 The actions of
RhoA are mediated by Rho effectors such as p160ROCK (Rho-kinase)
which can phosphorylate multiple target proteins.7
In addition to mechanisms which activate VSMCmigration, there are
endogenous mechanisms which maintain quiescence, thereby prevent-
ing migration. At the level of intracellular signalling, it is clear that
increases in cyclic adenosine monophosphate (cAMP) can inhibit
growth-factor-induced VSMC migration.11 Although currently untest-
ed, this approach could potentially indicate that cAMP-activating drugs
may be useful in drug-eluting stents to decrease neointimal hyperplasia.
Indeed, prostacyclin and its analogues have been recognized for some
time to inhibit neointimal hyperplasia in animal models via a variety of
mechanisms, including elevation of intracellular cAMP concentra-
tions.12–15 The mechanisms involved in cAMP-mediated inhibition of
VSMC migration are not clear. Until recently the downstream effects
of increased cAMP were assumed to be predominantly via the well-
described mediator, protein kinase A (PKA). However, cloning of the
cAMP-binding protein, exchange protein directly activated by cAMP
(Epac), has offered additional cAMP-dependent mechanisms with
different downstream consequences.16,17 Epac has 2 known isoforms,
Epac1 and Epac2, with little functional difference ascribed to their ef-
fects. Epac is one of a family of guanine nucleotide exchange factors
for the monomeric G-protein Rap1.17 Rap1 has several different func-
tions dependent upon cell type and is frequently associated with regu-
lation of the cell cytoskeleton.18 The Epac-Rap1 pathway is intimately
involved in regulating cell migration and cell-cell interactions in a cell
type dependent manner.19,20 Both Epac/Rap1 and PKAmay be involved
in relaxation of smooth muscle and could inhibit VSMC proliferation,
although their role in VSMC migration is still unknown.21–23
In the current study, we have examined VSMC migration and the
effects of increasing cAMP using the prostacyclin analogue beraprost.
We now demonstrate that at therapeutically relevant concentrations
of beraprost, VSMC migration is inhibited via a divergent mechanism
dependent on cAMP and Epac, but does not involve PKA. These
findings indicate that cAMP-producing agonists such as beraprost
may be useful in decreasing restenosis by preventing VSMC migra-
tion. The study also indicates Epac/Rap1 as a potential therapeutic
target.
2. Methods
An expanded Methods section is available in Supplementary material.
2.1 Primary cell culture of human vascular
smooth muscle cell
Saphenous veins were obtained from patients undergoing coronary artery
bypass graft surgery after obtaining written consent under procedures
approved by the local ethical committee (reference 06/S0802/26). These
procedures conform to the principles outlined in the Declaration of
Helsinki. VSMC were cultured from vascular explants and maintained as
previously described. All cells used were between passages 3–8. For
ex vivo organ culture, veins were incubated in 30% bovine calf serum for
14 days and medium changed every 48 h.
2.2 Chemotaxis assays
Cells were kept in serum-free medium for 24 h and seeded into a 48 multi-
well chemotaxis chamber as per the manufacturer’s instructions. Migrated
cells bound to the underside of the membrane were mounted onto a
microscope slide and the cells counted using ImageJ. All samples were
completed in duplicate.
2.3 Bromodeoxyuridine cell proliferation assay
Cells were plated into 96-well plates in 0.1% FCS DMEM for 24 h. Treat-
ment medium was added along with the bromodeoxyuridine (BrdU) label
for a further 24 h. The BrdU assay was carried out as per manufacturer’s
instructions and repeated in triplicate.
2.4 SDS–PAGE electrophoresis/
immunoblotting
Protein extracts were prepared and subjected to SDS–PAGE followed by
immunoblotting as previously described.24
2.5 Immunofluorescence staining
Cells were serum starved for 24 h and, following treatment, were fixed in
3% paraformaldehyde as previously described.24 Cells were imaged using a
Zeiss 710 scanning confocal microscope with a 40× objective. During
confocal imaging comparing different cell treatments, settings on the micro-
scope were not changed (including contrast, aperture, and laser strength).
Experiments were repeated in triplicate.
2.6 siRNA transfection
Knockdown of specific proteins was carried out as previously described for
human VSMC.24 Cells were transfected with either 37.5 nmol/L scrambled
siRNA (Dharmacon) or 18.75 nmol/L of each PKAa and -b catalytic subunit
siRNA (validated siRNA from Qiagen) or 18.75 nmol/L Rap1A and Rap1B
SMARTpool siRNA (validated siRNA fromDharmacon) using Lipofectamine
RNAiMAX (Invitrogen) according to the manufacturer’s instructions. For se-
quence data, see Supplementarymaterial online, Table S1. The cells were ser-
um starved the following day for 24 h and then the protein was extracted for
immunoblotting or the cells were used in the chemotaxis chamber.
2.7 Fluorescence resonance energy transfer
A human aortic smooth muscle cell nucleofector kit cc-2571 from Lonza
was used to introduce the cDNA into the VSMC. For experiments investi-
gating the Epac protein, 8 mg CFP-Epac-YFP cDNA was used (kindly do-
nated by Dr. Kees Jalink, The Netherlands Cancer Institute, Amsterdam,
The Netherlands). The PKA cDNA consists of a regulatory subunit con-
struct and a catalytic subunit construct (kind gift from Prof. Manuela Zacco-
lo, University of Glasgow, Glasgow, UK). The ratio of the two PKA cDNA
was optimised and 2 mg of the donor and 3 mg of the acceptor were added.
Briefly cells were passaged and transferred to an electroporation cuvette
with the cDNA and nucleofector solution and transfected according to
manufacturer’s instructions. The cells were plated in single glass-bottom
dishes and following stimulation time-lapse videos of transfected VSMC
were captured using a Leica AF6000LX imaging system which captures sim-
ultaneously in cyan fluorescent protein (CFP), yellow fluorescent protein
(YFP), and FRET configured channels. Correction factors were entered
into the software to correct for channel bleed-through and background
fluorescence. The correction factors have previously been generated using
control experiments described.25 Images of 378 ms duration were cap-
tured every minute with a Roper Coolsnap 1392 × 1040 pixel camera
with 4 × 4 binning. The Leica 11504119 Fret EX filter separated the fluor-
escent channels: a CFP donor channel (excitation at wavelength 427+
5 nm and emission at 482+ 15 nm), an FRET channel (excitation at wave-
length 427+ 5 nm and emission at 542+ 13 nm), and a YFP channel
(excitation at wavelength 500+ 6 nm and emission at 542+ 13 nm).
These images were used to create a pseudocolour sensitized FRET image
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for each time point using specific algorithms.25 Regions of interest were
traced using the Leica Advanced Fluorescence software and FRET values
recorded. The FRET data are displayed as percentage change from the ini-
tial control readings before treatments were added at 5 min, with values
.0% reflecting protein activation and values ,0% reflecting protein inacti-
vation. All experiments were performed in duplicate.
2.8 Rap1 and Rho pull-down assay
Pull-down assays in human VSMC were performed as previously de-
scribed.26 Cells were plated in 75 cm2 flasks and grown to 80–90% conflu-
ent. The cells were serum starved for 24 h. After this time period,
treatment medium was added to the flasks for 5–10 min for the Rap1 ex-
periments and 30 min for the Rho experiments. After incubation the Rap1
or Rho pull-down assay was carried out as per manufacturer’s instruction
(Thermo Scientific). Briefly, the cells were scraped and centrifuged at
16 000 g for 15 min at 48C. Two controls were used including the GTPgs
(positive control) and GDP (negative control) throughout the assay. The
lysates were placed into spin cups with a GST–fusion protein of the Rap1-
binding domain from human RalGDS to pull down the active Rap1 protein
or the Rhotekin-binding domain along with glutathione agarose resin to pull
down the active Rho protein. Immunoblotting was then carried out with
either an anti-Rap1 or anti-Rho antibodies for the detection of the
GTP-bound active form of the protein.
2.9 Statistics
All experiments were performed with either three or more individual pa-
tient vein explants. Data are expressed as the mean+ SEM. For experi-
ments that were performed in duplicate or triplicate, replicates were
averaged and average values used to calculate the mean.
A paired t-test was performed for the Rap1 RT-PCR (supplementary ma-
terial online, Figure S2B) and Figure 6D, where the same cells at the same
passage were used with different treatments. A two-way ANOVAwas per-
formed with Dunnett’s post hoc test for the FRET data to compare each
timepoint with different treatments. All other experiments were analysed
with a one-way ANOVA with Dunnett’s post hoc test. A P value of ,0.05
was taken as statistically significant.
3. Results
3.1 Beraprost inhibits
growth-factor-induced migration,
but not proliferation, of human VSMC
To determine whether beraprost can inhibit human VSMC migration,
primary cultured VSMC were seeded onto membranes in a modified
Boyden chemotaxis chamber and incubated with beraprost. After 4 h
in the chamber, cells had significantly migrated towards a chemogradi-
ent established by 10 ng/mL PDGF. Beraprost (1, 10 and 100 nmol/L)
significantly inhibited VSMC migration (Figure 1A). Similar results were
obtained with another prostacyclin analogue iloprost (not shown). To
ensure that changes in migration were not due to the actions of bera-
prost on the mitogenic effects of PDGF, BrdU incorporation was
assessed (Figure 1B). At 4 h, BrdU incorporation was not significantly
increased by PDGF (not shown). Furthermore, at 24 h, although
VSMC incubated with PDGF had significantly increased BrdU incorpor-
ation, the addition of beraprost did not significantly alter this effect.
3.2 PKA and Epac activation inhibit
migration
Since beraprost inhibits PDGF-induced VSMC migration, we investi-
gated the downstream mediators involved. VSMC were incubated
with cAMP analogues that preferentially activate either PKA or Epac
and PDGF-induced migration was determined. VSMC were incubated
with either 8-bromoadenosine 3′,5′-cyclic monophosphorothioate
Sp-isomer (Sp-cAMPS) (Epac and PKA agonist), N6-phenyladenosine-
3′,5′-cyclic monophosphate (6-Phe-cAMP) (selective PKA agonist) or
8-(4-chlorophenylthio)-2′-O-methyladenosine 3′,5′-cyclic monopho-
sphate (8-Me-cAMP) (selective Epac agonist). All of these cAMP analo-
gues inhibited PDGF-induced VSMC migration (Figure 2A). The effects
of 6-Phe-cAMP and 8-Me-cAMP were not additive (Figure 2B) despite
the concentrations used being submaximal (supplementary material
online, Figure S1). Differences in the total migration achieved with
PDGF can be observed in Figure 2A compared with Figure 2B. This is
due to variation within the patient samples obtained.
3.3 At therapeutic concentrations,
beraprost activates Epac but not PKA
in VSMC to inhibit migration
Pharmacokinetic studies of beraprost in humans have determined that
the peak plasma concentration of beraprost which can be achieved is
up to 345 ng/mL (1 nmol/L).27 This peak plasma concentration
Figure 1 Beraprost inhibits migration in human VSMC but does not
alter proliferation. (A) VSMC were seeded into the top well of a
chemotaxis chamber and PDGF (10 ng/mL) was added with or with-
out increasing concentrations of beraprost (1–100 nmol/L) to the
bottom well. PDGF-induced migration was inhibited at all concentra-
tions of beraprost examined, n ¼ 6. (B) VSMC were treated with
PDGF with or without beraprost for 24 h. Increasing concentrations
of beraprost had no effect on PDGF-induced BrdU incorporation,
n ¼ 3. Data are shown as mean percentage+ SEM. ***P, 0.001,
*P, 0.05.
J.S. McKean et al.548
by guest on O
ctober 28, 2015
D
ow
nloaded from
 
does not increase with multiple doses. To determine whether bera-
prost activates either Epac or PKA at this therapeutically relevant con-
centration, we transfected VSMC with fluorescence resonance energy
transfer (FRET) sensors for Epac or PKA. Single cells were stimulated
with either 1, 10, or 100 nmol/L beraprost and FRET activity for each
probe was measured and expressed as relative FRET activity of the
whole cell. 1 nmol/L beraprost induced a significant decrease in FRET
activity (increase in sensor activation) of the Epac probe 1 min after
incubation compared with vehicle-treated cells (drug added after
5 min of baseline measurement). This reached a peak between 2 and
5 min after beraprost addition and decreased thereafter (Figure 3A).
However, 1 nmol/L beraprost did not change the activity of the PKA
FRET probe in VSMC over 15 min, indicating that PKA is not activated
at this concentration (Figure 3B). Additional experiments carried out
over longer periods of up to 60 min duration also did not reveal any
significant change in PKA activity as assessed by both the % change in
FRET activity (not shown) or area under the curve (Figure 3C). Similarly,
incubation with 10 nmol/L beraprost did not result in a change in PKA
FRET probe activity compared with untreated cells over a 60 min time-
course (Figure 3C). Epac activation, however, was significantly increased
over a 60 min timecourse by incubation with 10 nmol/L beraprost
(Figure 3C). Notably, higher concentrations of beraprost (100 nmol/L)
produced a significant increase in both Epac and PKA FRET activity in
cells transfected with the respective probes (Figure 3C). To ensure that
the observed differences between activity of the Epac and PKA FRET
probes to beraprost were not due to different sensitivities of the differ-
ent sensors, VSMC were incubated with increasing concentrations of
forskolin, an adenylate cyclase activator and FRET activity was mea-
sured. Changes in the magnitude and timecourse of FRET activity
were not significantly different comparing Epac and PKA probes in re-
sponse to 1 and 10 mmol/L forskolin (supplementary material online
data, Figure S2). These data suggest that Epac, but not PKA, is activated
by a therapeutically relevant concentration of beraprost to inhibit
VSMC migration.
In addition, we examined an ex vivo model of hyperplasia to deter-
mine whether Epac could prevent hyperplasia in blood vessels. Four se-
quential human saphenous vein segments (from the same vein) were
either; (i) fixed immediately (control), (ii) cultured for 14 days in 30%
FBS-containing medium, (iii) cultured for 14 days in serum-free medium
with 50 mmol/L Epac analogue 8-Me-cAMP, or (iv) cultured for 14 days
in 30% FBS-containing medium and 50 mmol/L Epac analogue
8-Me-cAMP. Subsequent analysis of saphenous vein paraffin-embedded
sections subjected to H&E staining revealed that the serum-induced
increase in vessel wall thickness was significantly reversed by incubation
with the Epac analogue (Figure 3D).
3.4 Therapeutic concentrations of
beraprost inhibit VSMC migration
via an Epac-Rap-1 pathway
An siRNA-mediated decrease in the expression of Epac1 and Epac2
was not possible in human saphenous vein VSMC (see Supplementary
material online, Methods). Alternatively we targeted Rap1 expression.
VSMCwere incubated with siRNA-specific for Rap1A and Rap1B. Rap1
(both Rap1A and Rap1B) protein expression was significantly de-
creased by 81+ 17% compared with cells incubated with scrambled
siRNA (Figure 4A). This decrease in Rap1 protein expression had no sig-
nificant effect on PDGF-induced VSMC migration as assessed using a
modified Boyden chamber (Figure 4A). However, inhibition of migration
by 1 nmol/L beraprost was significantly reversed in these cells com-
pared with cells incubated with scrambled siRNA or control (untrans-
fected) cells indicating the involvement of the Rap1 pathway in the
anti-migratory effects of beraprost. To determine the potential involve-
ment of PKA, VSMC were transfected with siRNA which resulted in
74+ 11% decrease in PKA catalytic subunit protein expression
(Figure 4B). This knockdown in PKA protein expression did not pro-
duce any change in either PDGF-induced migration or the inhibitory
effect of 1 nmol/L beraprost (Figure 4B). To ensure that the level of
decrease in PKA protein expression was sufficient to induce a
Figure 2 cAMP signalling can inhibit human VSMC migration via
multiple mediators. VSMC were added to the chemotaxis chamber
in the presence of PDGF (10 ng/mL). (A) PDGF-induced migration
was inhibited in the presence of Sp-cAMPS (20 mmol/L), 6-Phe-cAMP
(5 mmol/L), or 8-Me-cAMP (2 mmol/L), n ¼ 5. (B) The simultaneous
addition of 6-Phe-cAMP (5 mmol/L) and 8-Me-cAMP (2 mmol/L) in
the presence of PDGF had no further effect on VSMC migration
in comparison with 6-Phe-cAMP or 8-Me-cAMP alone, n ¼ 5,
**P, 0.01, ***P, 0.001. Data are expressed as mean+ SEM Per-
centage of migration in comparison to the control.
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functional change, we examined phosphorylation of vasodilator-
stimulated phosphoprotein (VASP), a known downstream target
protein of PKA. In cells transfected with scrambled siRNA, 100 nmol/L
beraprost incubation (which activates PKA, Figure 3E) resulted in an in-
crease in VASP phosphorylation within 60 min (Figure 4C). This increase
was significantly inhibited in cells transfected with PKA siRNA.
The above results suggest that beraprost inhibits migration via acti-
vation of the Epac/Rap1 pathway. To ensure that beraprost activated
Rap1 in human saphenous vein VSMC, we used a pull-down assay
specific for GTP-bound Rap1. Forskolin induced an increase in Rap1 ac-
tivation as determined by elevated GTP binding within 5 min of incuba-
tion (Figure 5A). Beraprost also resulted in Rap1 activation by 2-fold
Figure 3 Beraprost at therapeutic concentrations activates Epac but not PKA. (A) The addition of 1 nmol/L beraprost (at timepoint 5 min) to VSMC
transfected with the Epac sensor resulted in a time-dependent significant decrease in FRET activity (denoting an increase in Epac activation) compared
with control (no beraprost added), n ¼ 5. Data are expressed as percentage change+ SEM in FRET activity. (B) 1 nmol/L beraprost incubation in VSMC
transfected with the PKA sensor produced no significant change in FRET activity compared with vehicle-treated cells throughout the timecourse
examined (up to 60 min, 15 min shown), n ¼ 6. Data are expressed as percentage change+ SEM in FRET activity, drug incubation starts at 5 min time-
point. (C ) Bar graph showing area under the curve (AUC) for FRET activity during 60 min of beraprost incubation. Beraprost-treated cells (1, 10, and
100 nmol/L) are compared with their respective vehicle-treated controls, (n ¼ 4–7. All three concentrations of beraprost significantly increased Epac
activation whereas only the highest concentration examined (100 nmol/L) significantly increased PKA activation. (D) Vessel wall thickness of H&E stained
sections from vessels cultured ex vivo for 14 days was measured using ImageJ and compared with sections from vessel segments fixed immediately for
microscopy. Incubation with 50 mmol/L 8-Me-cAMP significantly decreased the serum-induced hyperplasia (n ¼ 3 veins from different subjects).
*P, 0.05, **P, 0.01, ***P, 0.001.
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compared with control after 5 min incubation. This remained elevated
at 10 min but was not significant (Figure 5B).
3.5 Epac1 is expressed at the leading edge
of VSMC whereas PKA is present at
perinuclear locations
To determine which isoforms of Epac are expressed in human saphe-
nous vein VSMC, we performed immunocytochemistry using specific
antibodies for Epac1 and Epac2. Immunoblots and real-time PCR deter-
mined that Epac1 and Epac2 are expressed in these cells (Supplemen-
tary material online, Figure S3). VSMC on coverslips were subjected to a
scratch and left for 24 h to induce migration. Cells migrating towards
the scratch centre with a clearly visible leading edge were analysed.
Epac1 was located predominantly at the leading edge (Figure 5C).
Epac2 had a more even distribution throughout the cell although it
was also present at the leading edge. PKA, however, was found almost
exclusively in the perinuclear region. Incubation with PDGF did not
alter the localization of Epac1, Epac2 or PKA (Figure 5D). Beraprost
treatment also did not change the distribution of these proteins
(Supplementary material online, Figure S4).
3.6 Beraprost prevents actin cytoskeleton
re-arrangement at the leading edge during
migration by inhibiting RhoA
As therapeutic concentrations of beraprost activated the Epac /Rap1
pathway, we examined potential downstreammechanisms which might
contribute to the inhibitory effect on migration. Rap1 has previously
been shown to inhibit RhoA in several cell types including some
smooth muscle cell types.21 We firstly examined the role of RhoA in
migration of human saphenous vein VSMC. The Rho-kinase inhibitor
Figure 4 Inhibition of human VSMCmigration by therapeutic concentrations of beraprost requires Epac/Rap1 activation but not PKA. (A) Transfection
of Rap1 siRNA significantly decreased Rap1 protein in VSMC by 81% in comparison to scrambled siRNA. In the chemotaxis chamber, 1 nmol/L beraprost
had no effect on PDGF-induced migration in Rap1 siRNA-treated VSMC. Data are expressed as mean percentage of migration in comparison to the
control+ SEM, n ¼ 4. (B) PKA siRNA to A and B catalytic subunits of PKA decreased PKA protein expression in VSMC by 74% in comparison to
the scrambled siRNA. PKA siRNA-treated VSMC were added to the chemotaxis chamber. 1 nmol/L beraprost inhibited PDGF-induced migration des-
pite decreased PKA expression. Data are expressed as mean percentage of migration in comparison to the control+ SEM, n ¼ 4. (C) The effect of PKA
siRNA on phosphorylation of the PKA downstream effector, VASP, was examined. VASP phosphorylation induced by 100 nmol/L beraprost (a concen-
tration which activates both PKA and Epac) after 1 h incubation was significantly decreased in the PKA siRNA-treated VSMC compared with cells trans-
fected with scrambled siRNA and control (untransfected) cells. Data are displayed as p-VASP/total VASP, mean+ SEM, n ¼ 4. *P, 0.05, **P, 0.01,
NS ¼ non-significant.
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Y27632 (1 mmol/L) had a similar inhibitory effect on PDGF-induced
migration compared with 8-Me-cAMP (Figure 6A). This effect obtained
at 1 mmol/L Y27632 was submaximal (Supplementary material online,
Figure S5). This suggests that activation of the RhoA/Rho-kinase path-
way is required for PDGF-induced migration. The effects of Y27632
and 8-Me-cAMP combined were not additive. Using Rhotekin
pull-down assays specific for GTP-bound RhoA, we observed that
PDGF activated RhoA in human VMSC over a 30 min timecourse
(Figure 6B). Co-incubation of the cells with 1 nmol/L beraprost signifi-
cantly inhibited RhoA activation. In addition, 8-Me-cAMP inhibited
PDGF-induced RhoA activation at the same concentration used to
inhibit VSMC migration (Figure 6C). As a comparison, the effect of
Figure 5 Beraprost activates Rap1 and Epac1 localises to the leading edge. (A) Incubation of 10 mM forskolin significantly increased Rap1 association
with GTP within 5 min. Data are displayed as Rap1 GTP/total Rap1, mean+ SEM, n ¼ 4. (B) Rap1 GTP was also significantly increased in following in-
cubation with of 1 nmol/L beraprost after 5 min. n ¼ 4. (C) Epac1 is predominantly localized to the leading edge in migrating VSMC stimulated for 24 h
with PDGF. Epac2 localization occurs throughout the cell and the PKA is localized predominantly at perinuclear sites, n ¼ 3. Images show representative
cells, scale bar represents 5 mm. (D) The location of Epac1, Epac2, and PKA were assessed by intensity measurements. Locations for each protein were
confirmed and did not change following PDGF incubation. Data are expressed as the intensity mean value of the leading edge in comparison to the
cytoplasm of the VSMC, n ¼ 3, *P, 0.05, **P, 0.01, ***P, 0.001.
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the PKA agonist 6-Phe-cAMP on PDGF-induced RhoA activation was
also examined (Supplementary material online, Figure S6). Direct PKA
stimulation also inhibited RhoA activation, although this effect will not
be involved in beraprost-induced inhibition of migration (see Figure 3).
As RhoA is an important regulator of the actin cytoskeleton, we deter-
mined whether beraprost might prevent PDGF-induced effects on
F-actin. F-actin filaments observed at the leading edge in PDGF-treated
cells, as assessed using immunolocalization, were significantly de-
creased following co-incubation with 1 nmol/L beraprost (Figure 6D).
4. Discussion
Preventing migration of VSMC after angioplasty/stenting or vein grafting
following bypass surgery is a promising but untested therapeutic target.
Drugs which target VSMC migration would decrease the growth of
neointima and thereby reduce restenosis. In the current study, human
saphenous vein VSMC was examined in vitro to determine the potential
of cAMP-producing drugs to inhibit VSMCmigration. Beraprost, a pros-
tacyclin analogue, was studied as this has already been indicated as po-
tentially useful in some cardiovascular disease states and has therefore
direct clinical relevance.27 This was assessed at therapeutically relevant
concentrations comparable with those achievable in patient plasma.27
We reveal that beraprost can inhibit growth-factor-induced VSMC mi-
gration at these therapeutic concentrations. The mechanisms involved
in this inhibitory effect occur via activation of the cAMP-activated bind-
ing protein Epac but do not involve the well characterized and more
typical cAMP effector PKA. In our experiments, PKA was not activated
by beraprost at clinical concentrations and PKA siRNA did not inhibit
Figure 6 Beraprost inhibits RhoA activation and leads to inhibition of F-actin re-arrangement. (A) PDGF-induced migration of VSMC in the chemotaxis
chamber was inhibited in the presence of Y-27632 (1 mM) or 8-Me-cAMP (2 mM); however, there was no additional inhibition of migration when VSMC
were treated with Y-27632 and 8-Me-cAMP in combination. Migration data are expressed as a % of control, n ¼ 3. (B) Using a Rhotekin pull-down assay,
PDGF incubation for 30 min significantly increased GTP-bound RhoA. Simultaneous incubation with 1 nmol/L beraprost significantly decreased
Rho-GTP compared with PDGF alone. Data are expressed as Rho-GTP/Rho total, n ¼ 4. (C) Incubation with 2 mM 8-Me-cAMP significantly inhibited
PDGF-induced Rho-GTP binding in VSMC as assessed by Rhotekin pull-down assay. Data are expressed as Rho-GTP/Rho total, n ¼ 3. (D) VSMC in-
cubated with PDGF had extensive F-actin expression at the leading edge. Addition of 1 nmol/L beraprost inhibited F-actin formation at the leading edge
in comparison to PDGF alone. Representative images are shown. Data are expressed as the intensity mean value of the leading edge in comparison to the
cytoplasm, n ¼ 3. *P, 0.05, **P, 0.01, ***P, 0.001. Scale bar ¼ 5 mm.
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the beraprost-induced anti-migratory response. These results demon-
strate that cAMP-producing agonists such as beraprost may help slow
restenosis following angioplasty by inhibiting VSMC migration through
Epac activation.
Until very recently, the functional roles of Epac in VSMC were un-
known. Studies using Epac selective activators have now indicated
that Epac may be involved in the vasculoprotective effects of cAMP,
such as vasorelaxation of VSMC and an inhibition of VSMC prolifer-
ation.21– 23 Activation of Epac via either a direct Epac activator or a
cAMP-producing membrane receptor agonist, such as isoproterenol,
can produce a vasodilatory effect. This occurs via an increase in Rap1
activity and subsequent inhibition of RhoA resulting in calcium desen-
sitization of myosin II phosphorylation.21 In addition, Epac can also ac-
tivate calcium-sensitive potassium channels in arteries leading to
hyperpolarization which decreases calcium entry via voltage-gated cal-
cium channels and also results in vasodilation.22 It is not clear whether
this effect on potassium channels is dependent on Rap1 signalling. Add-
itionally, Epac can inhibit proliferation in rat and human VSMC.23,28 This
effect, at least in rat VSMC, is synergistic with PKA as Epac activation
alone was not sufficient to inhibit the proliferative effect.22 In the pre-
sent study we did not detect any inhibition of human VSMC prolifer-
ation, even at relatively high concentrations of the cAMP-producing
agonist beraprost, which can activate both PKA and Epac. However,
our current study now indicates that Epac activation (in the absence
of PKA activation) is sufficient to inhibit human VSMC migration.
A recent contradictory study has indicated that a synthetic Epac acti-
vator enhances rat VSMC migration, although therapeutically relevant
concentrations of cAMP, such as those generated by cAMP-producing
agonists, were not assessed.29 This is in contrast to most studies
which indicate a protective role for cAMP signalling in the vasculature.
We have also examined migration in rat VSMC and although no en-
hancement was observed with a synthetic Epac agonist, we also could
not reproduce our results with regard to the inhibitory effects on
human VSMC migration (results not shown). This suggests that there
are clear species differences which will be important in determining
translational applicability. Regardless, we provide evidence here that
Epac is a novel drug target which could potentially be exploited to
limit restenosis.
An important finding of this study is that Epac and PKA are
differentially regulated in VSMC by varying the concentration of a
cAMP-producing agonist. At lower beraprost concentrations (directly
comparable to those achieved in vivo), only Epac is activated while at
higher beraprost concentrations both Epac and PKA are activated.
This indicates that lower levels of cAMP production lead to Epac acti-
vation alone, although this was not directly measured in our study. Such
data correspond with that previously observed in cardiac fibroblasts
and provides further evidence for the relevant physiological cAMP af-
finities for Epac vs. PKA.19 Other than these potential differences in
cAMP affinity, we have also uncovered further evidence which indicates
divergent functions of Epac and PKA. Our study demonstrates that
Epac1 is localized predominantly at the leading edge of migrating
VSMC cells and is therefore situated at the main site for directional mi-
gration. This is in contrast to PKA which has a perinuclear localization
relatively distant from both the leading and trailing edge. These distinct
localizations may indicate a compartmentalization of signalling with
regard to these mediators. Both the potentially lower cAMP affinity to-
gether with differences in localization indicate that Epac1 may be more
likely (compared with PKA) to be part of the regulation of migration,
acting as a brake on leading edge progression.
Although studies have demonstrated the potential importance of
Epac in VSMC function, the downstream signalling of Epac is highly rele-
vant to fully understand the mechanisms involved. We reveal that the
inhibition of migration induced by Epac is dependent on the subsequent
activation of Rap1 which in turn inhibits RhoA activation. The RhoA/
Rho-kinase pathway is essential for PDGF-induced migration in human
VSMC and is a well-described regulator of the cell cytoskeleton.4 We
have also demonstrated that Epac activation inhibits migration by pre-
venting rearrangement of the actin cytoskeleton at the leading edge
(the site of Epac1 localisation). This likely occurs via Rap1-mediated in-
hibition of RhoA. Evidence for an important role of Rap1 in VSMC func-
tion has been recently demonstrated using Rap1b2/2 mice. These
mice develop hypertension in part via functional changes to VSMC
and this indicates an essential role of Rap1 (and possibly Epac) in main-
taining normal vascular physiology.30 With regard to the Rap1-induced
inhibition of RhoA, other studies have previously demonstrated this
link although not in relation to VSMCmigration.21We now provide evi-
dence of the importance of this Rap1/RhoAmechanism in a pathologic-
ally relevant process and this is summarized in Figure 7.
An important part of our study has demonstrated that the clinically
approved drug beraprost activates Epac at therapeutically relevant con-
centrations. Orally-active beraprost is currently used in the treatment
of pulmonary hypertension in some countries and may have clinical
benefits in peripheral vascular disease.27 It must be acknowledged
that, in addition to the short half-life, beraprost also has side-effects
that could preclude this drug from becoming a routine option following
angioplasty.31 However, recent developments in technology, including
drug-eluting stents and encapsulation of beraprost in slow release na-
noparticles, now provide a route of administration which results in
more targeted action with lower systemic doses required.3,32 Such im-
provements in drug delivery would decrease side-effects and increase
its therapeutic potential. Beraprost is generally cardioprotective via its
vasodilatory and anti-platelet effects. It is a prostacyclin analogue which
binds to prostanoid receptors leading to activation of adenylate cyclase
via the heterotrimeric G-protein, Gs. It has a relatively short half-life
Figure 7 Schematic diagram of proposed mechanism of action of
beraprost-induced inhibition of VSMC migration. PDGF produces mi-
gration via activation of RhoA resulting in a rearrangement of actin fila-
ments. Beraprost, acting on IP receptors, stimulates cAMP production
activating Epac, which in turn leads to GTP-binding of Rap1. GTP-
bound Rap1 inhibits RhoA preventing actin reassembly and ultimately
decreasing migration.
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in vivo and therefore the maximum concentration which can be
achieved in plasma is limited to 1 nmol/L.27 We now demonstrate
in human VSMC that this therapeutically relevant concentration of be-
raprost activates Epac. This suggests that many of the clinically benefi-
cial effects may in fact arise from Epac activation. Our results also
indicate that beraprost activation of Epac/Rap1 may be useful in pre-
venting restenosis following angioplasty by blocking VSMC migration.
Indeed a recent study has examined the effects of beraprost in an
in vivomodel of in-stent restenosis.12 These authors have demonstrated
that intravenous beraprost treatment during stent emplacement sur-
gery significantly limited neointimal thickening after 4 weeks although
the intracellular mechanisms were not assessed. Our results now sug-
gest that an inhibition of migration may explain the observed beneficial
effects of prostacyclin analogues in vivo.12 Together these data provide
evidence of a potential therapeutic benefit of this drug target in
restenosis.
In conclusion, we have revealed, for the first time, that therapeutic-
ally relevant concentrations of the prostacyclin analogue beraprost can
inhibit VSMC migration via activation of the cAMP effector Epac. The
mechanism of this Epac-mediated inhibition is via activation of Rap1
and subsequent inhibition of RhoA preventing actin cytoskeletal
changes. This indicates that cAMP-producing agonists such as beraprost
may be beneficial following angioplasty to prevent neointimal
hyperplasia.
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